Deciphera Pharmaceuticals stock was surging Monday after the biopharmaceutical company announced it was being acquired by Japan’s ONO Pharmaceutical for $2.4 billion. According to a joint news ...

Deciphera Pharmaceuticals Inc. said Monday it has agreed to be acquired by Japan’s Ono Pharmaceutical Co. Ltd in an all-cash deal valued at $2.4 billion. Under the terms of the deal, Ono will ...

Shares in Deciphera Pharma went into freefall on Friday after top-line results of a phase 3 trial of its Qinlock in rare cancer gastrointestinal stromal tumour (GIST) dashed its hopes of moving ...

Japan’s Ono Pharma has bolstered its cancer pipeline with a $2.4 billion agreement to buy Deciphera Pharma of the US and its fast-growing gastrointestinal stromal tumour (GIST) therapy Qinlock.

The FDA previously granted Fast Track designation and Priority Review for ROMVIMZA, which was developed by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly owned subsidiary of Ono.

Deciphera in late 2008 signed an 18-month lease for 7,700 square feet of laboratory space owned by Kansas University at Bob Billings Parkway and Wakarusa Drive, near its operations at 4950 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...